
KAZMIRA®
THERAPEUTICS



Media Kit

Table of Contents



- 01 | Introduction to Kazmira Therapeutics
- 02 | Key Company Milestones
- 03 | Subject Matter Experts
- 04 | Frequently Asked Questions
- 05 | Notable News Coverage
- 06 | Recent Press Releases
- 07 | Media Contact Information

01

Introduction to Kazmira Therapeutics

Kazmira Therapeutics is a first-of-its-kind healthcare company dedicated to producing prescription-grade CBD with zero trace of THC, setting a new standard for cannabinoid medicine. As the only 503A compounding pharmacy in the U.S. focused exclusively on cannabinoid therapy, Kazmira enables providers to prescribe CBD that meets rigorous medical, safety, and regulatory requirements.

By eliminating THC entirely, Kazmira delivers compliant, consistent formulations designed to adapt to evolving regulations while expanding patient access to CBD as medicine.



02 | Key Company Milestones



Leading innovation in cannabinoid medicine

Kazmira was founded on a scientific breakthrough: the development of a proprietary method to isolate CBD from hemp with no trace of THC — a milestone that had not previously been achieved at scale. By fully removing the intoxicating component of the plant, the founders transformed CBD into a purified compound suitable for therapeutic benefit rather than recreational use.



Launching a first-of-its-kind pharmacy

In January 2026, Kazmira launched the nation's first 503A compounding pharmacy dedicated to cannabinoid therapy. Licensed providers in Colorado can now prescribe prescription-grade CBD to their patients, introducing a new clinical pathway for cannabinoid care. The company plans to expand access nationwide.



Meeting rigorous compliance and safety standards

Kazmira Pharmacy is LegitScript certified, underscoring its commitment to the highest standards of compliance, transparency, and patient safety. This nationally-recognized credential for healthcare operators validates Kazmira's rigorous pharmacy compliance, compounding quality, and regulatory practices — providing added assurance to healthcare practitioners and regulators that the company operates at the forefront of responsible cannabinoid science.



Aligning with shifting federal regulations

Kazmira Therapeutics remains fully compliant amid recent regulatory shifts impacting the cannabinoid landscape, as its pharmaceutical-grade non-intoxicating CBD eliminates regulatory scrutiny facing the current marketplace today. The company actively supports clearer, stronger regulation across the category, viewing it as a necessary step toward establishing CBD as a legitimate medicine grounded in science — not recreation.



For years, we've worked to remove the stigma around cannabis and move CBD from an over-the-counter product to evidence-based, pharmacy-dispensed medicine. With the launch of Kazmira Pharmacy, providers can work with their patients to prescribe personalized treatment that is best for their unique health concerns.

— Dr. Priyanka Sharma,
Co-Founder and Co-CEO

03 | Subject Matter Experts



Dr. Priyanka Sharma, Co-CEO

Priyanka Sharma, Ph.D., is the Co-Founder and Co-CEO of Kazmira Therapeutics and a trusted voice in the cannabis regulatory space, having previously served as a key scientific figure informing Colorado's cannabinoid marketplace for consumers. Coming from a chemical engineering background, Dr. Sharma's research on molecular modeling and nanoparticle functionalization have appeared in numerous peer-reviewed journals.



Pulak Sharma, Co-CEO

Pulak Sharma is the Co-Founder and Co-CEO of Kazmira Therapeutics and brings over a decade of experience in business development, corporate strategy, and leadership. Pulak played a key role in securing Perrigo's investment in Kazmira, driven by a vision to expand patient access to CBD therapies through national retail channels. He continues to lead the company with a long-term focus on making evidence-based cannabinoid therapies accessible to patients at scale.

03

Subject Matter Experts



Dr. Rachit Marwaha, MD, Medical advisor

Rachit Marwaha, MD, is a Medical Advisor to Kazmira Therapeutics and an internal medical physician with a strong focus on functional medicine and lifestyle-based care. Dr. Marwaha believes strongly in emphasizing nutrition, lifestyle modification, and personalized treatment plans to support patients' long-term health outcomes.



Dr. Gautham Oroskar, MD, Medical advisor

Gautham Oroskar, MD, is a Medical Advisor to Kazmira Therapeutics and a board-certified internal medicine physician practicing as an inpatient hospitalist in the Chicago area. Dr. Oroskar is involved in science research and third-party clinical study reviews examining the effectiveness of CBD to treat various medical disorders.

04 | Frequently Asked Questions



Q Is Kazmira's CBD the same as the CBD products sold in grocery stores or drugstores?



A No. Over-the-counter CBD products are sold as supplements, not medicines, and are not held to pharmaceutical standards for purity or potency. These products vary widely in CBD concentration, contain trace amounts of THC, or include other ingredients that can affect outcomes. Medical-grade CBD is produced under rigorous controls to ensure precise formulation, safety, and reliability.



Q I tried CBD before and it didn't help with my pain or anxiety. Why might that be?



A Many consumers do not experience benefits from over-the-counter CBD products as they lack sufficient potency, consistency, or purity. In some cases, products may include THC or other cannabinoids that alter the effect or cause unwanted side effects. Without standardized dosing and medical oversight, it can be difficult to achieve therapeutic results.



Q What medical conditions has CBD been studied on?



A CBD has been studied across a wide range of potential therapeutic applications, including pain management, mental health conditions such as anxiety, substance use disorder recovery, inflammation, and neurological disorders. Research into additional uses is ongoing, with many clinical studies still underway to better understand CBD's full medical potential.



We were working on a THC-free CBD product years before Congress announced action to remove products containing certain levels of THC. We understood that CBD can be effective without any trace of THC. We also understood that removal of THC was critical in order to get CBD to be viewed as a medicinal product."

— Pulak Sharma,
Co-Founder and Co-CEO



Q How does Kazmira Pharmacy work with providers?



A By operating the only 503A pharmacy dedicated exclusively to cannabinoid therapy, Kazmira empowers physicians in Colorado – and soon nationwide – to integrate CBD into patient treatment plans with confidence in quality, consistency, and regulatory compliance. A clinician can simply write a prescription, and the compound is mailed directly to their patient.



05 | Notable News Coverage



91.7 | 91.9 | 88.1 | APP | .ORG |

Rewriting the Rules for
CBD Medicine
December 2025

[READ NOW](#)

Forbes

Hemp Seed Oil Vs. CBD Oil: What's
The Difference?

December 2025

[READ NOW](#)



Federal marijuana policy finally
moves – but are you ready for what
comes next? Docs weigh in

December 2025

[READ NOW](#)

MedCity News

Regulations Needed to Improve
Clinical Adoption Of CBD as
Medicine

January 2026

[READ NOW](#)




06 | Recent Press Releases

PR Newswire®

First-of-its-kind medical grade cannabis pharmacy launches in Colorado

January 2026

READ NOW



When you take intoxication, impairment, and drug-testing concerns off the table, physicians can evaluate how their patients respond to CBD the same way they evaluate any other therapeutic compound. It becomes a therapeutic tool in their toolkit with a defined mechanism of action, not a supplement with weak clinician oversight.

— Dr. Gautham Oroskar or Dr. Rachit Marwaha, MD, Medical advisor



07 | Media Contact

KNB Communications
kazmira@knbcomm.com